for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Aldeyra Therapeutics Reaches Agreement With FDA To Use RASP as An Objective Sign For The Treatment Of Dry Eye Disease

June 4 (Reuters) - Aldeyra Therapeutics Inc:

* ALDEYRA THERAPEUTICS REACHES AGREEMENT WITH THE US FOOD AND DRUG ADMINISTRATION FOR THE USE OF RASP AS AN OBJECTIVE SIGN FOR THE TREATMENT OF DRY EYE DISEASE

* ALDEYRA - EXPECTS TO PROVIDE UPDATE ON PLANS, NDA NEEDS FOR REPROXALAP IN DRY EYE DISEASE POST RECEIPT OF FDA MEETING MINUTES, ANTICIPATED IN JULY Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up